Precision BioSciences (Nasdaq:DTIL) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

DTIL 주식 개요

는 미국에서 유전자 제거, 삽입, 절제 등 유전자 편집을 위한 생체 내 유전자 편집 치료법을 개발하는 첨단 유전자 편집 회사입니다.

DTIL 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	0/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

지난 5년 동안 수입이 매년 15.4% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

수익은 향후 3년간 연평균 24.9% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 크게 희석되었습니다.

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

의미 있는 시가총액이 없습니다. ( $70M )

+ 1 더 많은 위험

Precision BioSciences, Inc. 경쟁사

Cue Biopharma

NasdaqCM:CUE

US$71.5m

CollPlant Biotechnologies

NasdaqGM:CLGN

US$55.5m

Affimed

NasdaqGM:AFMD

US$89.4m

Elutia

NasdaqCM:ELUT

US$107.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Precision BioSciences
과거 주가
현재 주가	US$9.57
52주 최고치	US$21.90
52주 최저치	US$8.25
베타	1.74
11개월 변경	-24.88%
3개월 변경 사항	-26.27%
1년 변경 사항	-41.47%
33년 변화	-97.35%
5년 변화	-97.60%
IPO 이후 변화	-98.17%

최근 뉴스 및 업데이트

Recent updates

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Aug 06

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Jun 23

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Mar 14

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Dec 08

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Sep 02

Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt

Apr 19

Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)

Mar 21

Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely

Dec 31

Precision BioSciences: Uniquely Positioned

Oct 07

Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?

Sep 24

Precision BioSciences: The Right Profile To Progress

Aug 27

주주 수익률

	DTIL	US Biotechs	US 마켓
7D	-5.2%	2.1%	-0.5%
1Y	-41.5%	12.0%	24.2%

수익률 대 산업: DTIL 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: DTIL 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is DTIL's price volatile compared to industry and market?
DTIL volatility
DTIL Average Weekly Movement	10.1%
Biotechs Industry Average Movement	10.4%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: DTIL 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: DTIL 의 주간 변동성( 10% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2006	109	Michael Amoroso	www.precisionbiosciences.com

는 미국에서 유전자 제거, 삽입, 절제 등 유전자 편집을 위한 생체 내 유전자 편집 치료법을 개발하는 첨단 유전자 편집 회사입니다. 이 회사는 DNA 게놈 삽입, 삭제, 복구를 위한 게놈 편집 플랫폼인 아커스(ARCUS)를 제공합니다. 또한 B형 간염 표면 항원의 장기적인 감소를 목표로 공유 결합된 원형 DNA를 직접 절단 및 편집하여 제거하고 통합된 HBV DNA를 비활성화하기 위한 만성 B형 간염 바이러스(HBV) 치료용 PBGENE-HBV, m.3243 관련 원발성 미토콘드리아 근병증(PMM) 치료를 위한 PBGENE-PMM을 공급하고 있으며, 현재 IND 및 CTA 제출이 예정되어 있습니다.

Precision BioSciences, Inc. 기본 사항 요약

Precision BioSciences 의 수익과 매출은 시가총액과 어떻게 비교하나요?
DTIL 기본 통계
시가총액	US$65.65m
수익(TTM)	-US$19.99m
수익(TTM)	US$57.53m

1.2x

P/S 비율

-3.3x

P/E 비율

DTIL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
DTIL 손익 계산서(TTM)
수익	US$57.53m
수익 비용	US$0
총 이익	US$57.53m
기타 비용	US$77.52m
수익	-US$19.99m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.89
총 마진	100.00%
순이익 마진	-34.74%
부채/자본 비율	60.4%

DTIL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

DTIL 주식 개요

보상

위험 분석

Precision BioSciences, Inc. 경쟁사

NasdaqCM:CUE

US$71.5m

NasdaqGM:CLGN

US$55.5m

NasdaqGM:AFMD

US$89.4m

NasdaqCM:ELUT

US$107.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Recent updates

Precision Biosciences, Inc. Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate At the European Association for the Study of the Liver Congress

Precision BioSciences, Inc. to Report Q1, 2024 Results on May 13, 2024

Precision BioSciences, Inc., Annual General Meeting, Jun 04, 2024

Precision BioSciences, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency

Precision BioSciences, Inc. has filed a Follow-on Equity Offering.

Precision BioSciences, Inc. Receives Pre-IND Feedback from US FDA for PBGENE-HBV as It Advances Towards Clinical Readiness

Precision BioSciences, Inc. announced that it expects to receive funding from TG Therapeutics, Inc.

Precision Biosciences Announces Approval of First Clinical Trial Application of Arcus Gene Insertion Program by Partner iEcure

Precision BioSciences, Inc. Announces Publication in Nature Metabolism Supporting ARCUS In Vivo Gene Editing as a Potentially Curative Treatment for Mitochondrial Diseases

Precision BioSciences, Inc. Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Precision BioSciences Receives Approval from The Nasdaq Stock Market LLC to Transfer the Listing of its Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market

Price target decreased by 15% to US$2.60

Precision BioSciences, Inc. Announces Management Changes

Consensus revenue estimates increase by 47%

Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Price target decreased by 24% to US$5.07

Precision Biosciences, Inc. Provides Updates on Azer-Cel FDA Meeting, Potential Partnerships and Timing of in Vivo R&D Day

It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks

Precision Biosciences, Inc. Announces Oral Presentation of Positive Arcus Gene Editing Data At International Liver Congress 2023

Precision Biosciences, Inc. Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at American Society of Gene & Cell Therapy 26th Annual Meeting

Consensus revenue estimates increase by 17%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates fall by 27%

Price target decreased by 11% to US$6.00

Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, Its Lead Allogeneic Car T Clinical Candidate

Precision BioSciences, Inc. Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Less than half of directors are independent

Price target decreased to US$6.63

Precision BioSciences, Inc. Announces Raymond Schinazi Resigns from Board and as Chair of Nominating and Corporate Governance Committee and Member of Compensation Committee and Science and Technology Committee

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Precision BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Chief Financial Officer recently bought US$60k worth of stock

Precision BioSciences, Inc Announces Executive Promotions

Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles

Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Precision BioSciences Q2 2022 Earnings Preview

Precision BioSciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Precision BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million.

Precision BioSciences, Inc.(NasdaqGS:DTIL) dropped from Russell 2000 Dynamic Index

Chief Financial Officer recently bought US$51k worth of stock

Consensus forecasts updated

Price target decreased to US$10.63

Precision BioSciences, Inc. Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Precision Biosciences, Inc. Appoints Melinda Brown to its Board of Directors and Chair of the Board’s Audit Committee

Precision BioSciences, Inc. Appoints Juli Blanche as Chief People Officer

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind